期刊
KIDNEY INTERNATIONAL
卷 95, 期 6, 页码 1304-1317出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2019.02.022
关键词
cardiovascular disease; chronic kidney disease; congestive heart failure; hemodialysis; transplantation
资金
- KDIGO
- Abbott
- Akebia Therapeutics
- AMAG Pharmaceuticals
- Amgen
- AstraZeneca
- Boehringer Ingelheim
- Corvidia
- Fresenius Medical Care
- Keryx Biopharmaceuticals
- NxStage
- Relypsa
- Roche
- Sanifit
- Vifor Fresenius Medical Care Renal Pharma
The incidence and prevalence of heart failure (HF) and chronic kidney disease (CKD) are increasing, and as such a better understanding of the interface between both conditions is imperative for developing optimal strategies for their detection, prevention, diagnosis, and management. To this end, Kidney Disease: Improving Global Outcomes (KDIGO) convened an international, multidisciplinary Controversies Conference titled Heart Failure in CKD. Breakout group discussions included (i) HF with preserved ejection fraction (HFpEF) and nondialysis CKD, (ii) HF with reduced ejection fraction (HFrEF) and nondialysis CKD, (iii) HFpEF and dialysis-dependent CKD, (iv) HFrEF and dialysis-dependent CKD, and (v) HF in kidney transplant patients. The questions that formed the basis of discussions are available on the KDIGO website http://kdigo.org/conference/heart-failure-in-ckd/, and the deliberations from the conference are summarized here.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据